# Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

> **NCT02670551** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 488 (actual)

## Conditions studied

- Bipolar Disorder
- Depression

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02670551
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-17
- **Primary completion:** 2017-07-19
- **Final completion:** 2017-07-19
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670551, "Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02670551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*